Marieke van Son

23 GENERAL INTRODUCTION AND THESIS OUTLINE 76. Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recur- rence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967-87. 77. De Visschere PJL, Standaert C, Futterer JJ, Villeirs GM, Panebianco V, Walz J, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol. 2019;2(1):47-76. 78. van der Poel H, Grivas N, van Leeuw- en P, Heijmink S, Schoots I. The role of MRI for detection and staging of radio- and focal therapy-recurrent pros- tate cancer. World journal of urology. 2019;37(8):1485-90. 79. Philippou Y, Parker RA, Volanis D, Gnanapragasam VJ. Comparative On- cologic and Toxicity Outcomes of Sal- vage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecur- rent Prostate Cancer: A Meta-Regres- sion Analysis. European urology focus. 2016;2(2):158-71. 80. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research E. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and out- comes. Cancer. 2008;112(2):307-14. 81. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nature clinical practice Oncol- ogy. 2007;4(11):632-42. 82. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. The Journal of urology. 2007;178(6):2260-7. 83. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361(17):1704-6. 84. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature medicine. 2009;15(5):559-65. 85. Van Etten JL, DehmSM. Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer. 2016;23(4):R207-17. 86. Zhen L, Liu X, Yegang C, Yongjiao Y, Yawei X, Jiaqi K, et al. Accuracy of multi- parametric magnetic resonance imaging for diagnosing prostate Cancer: a sys- tematic review and meta-analysis. BMC cancer. 2019;19(1):1244. 87. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal pros- tate cancer. The Journal of clinical in- vestigation. 2013;123(11):4918-22. 88. Wysock JS, Lepor H. Multi-parametric MRI imaging of the prostate-implica- tions for focal therapy. Translational an- drology and urology. 2017;6(3):453-63. 89. Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Translational an- drology and urology. 2018;7(1):83-97. 90. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Ana- tomical Patterns of Recurrence Follow- ing Biochemical Relapse in the Dose Escalation Era of External Beam Radio- therapy for Prostate Cancer. The Journal of urology. 2015;194(6):1624-30. 91. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Anal- ysis of intraprostatic failures in patients treated with hormonal therapy and ra- diotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595-9. 1